Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1989 Sep 1;141(5):381–387.

Systemic adjuvant therapy for node-negative breast cancer.

A D Ginsburg 1, D J Perrault 1, K I Pritchard 1, G P Browman 1, P B McCulloch 1, J Skillings 1
PMCID: PMC1451405  PMID: 2670170

Abstract

In response to recent advice from the US National Cancer Institute concerning the use of systemic adjuvant therapy for node-negative breast cancer we reviewed the literature and found that several studies have shown evidence of a disease-free, but not an overall, survival advantage for treated patients. The benefits have been modest and may not outweight the cost and toxic effects of such therapy. Routine use does not seem to be justified. Factors must be identified to differentiate between patients at low risk and those at high risk. It should then be determined if adjuvant therapy is truly beneficial in those who are at high risk.

Full text

PDF
381

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987 Jul 25;2(8552):171–175. [PubMed] [Google Scholar]
  2. Andersen J. A., Fischermann K., Hou-Jensen K., Henriksen E., Andersen K. W., Johansen H., Brincker H., Mouridsen H. T., Castberg T., Rossing N. Selection of high risk groups among prognostically favorable patients with breast cancer. Ann Surg. 1981 Jul;194(1):1–3. doi: 10.1097/00000658-198107000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ashford A. R., Donev I., Tiwari R. P., Garrett T. J. Reversible ocular toxicity related to tamoxifen therapy. Cancer. 1988 Jan 1;61(1):33–35. doi: 10.1002/1097-0142(19880101)61:1<33::aid-cncr2820610107>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  4. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beck M., Mills P. V. Ocular assessment of patients treated with tamoxifen. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1833–1834. [PubMed] [Google Scholar]
  6. Clark R. M., Wilkinson R. H., Miceli P. N., MacDonald W. D. Breast cancer. Experiences with conservation therapy. Am J Clin Oncol. 1987 Dec;10(6):461–468. doi: 10.1097/00000421-198712000-00001. [DOI] [PubMed] [Google Scholar]
  7. Contesso G., Mouriesse H., Friedman S., Genin J., Sarrazin D., Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol. 1987 Sep;5(9):1378–1386. doi: 10.1200/JCO.1987.5.9.1378. [DOI] [PubMed] [Google Scholar]
  8. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation. Br J Cancer. 1988 Jun;57(6):608–611. doi: 10.1038/bjc.1988.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Crowe J. P., Hubay C. A., Pearson O. H., Marshall J. S., Rosenblatt J., Mansour E. G., Hermann R. E., Jones J. C., Flynn W. J., McGuire W. L. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat. 1982;2(2):171–176. doi: 10.1007/BF01806453. [DOI] [PubMed] [Google Scholar]
  10. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party. Br J Cancer. 1988 Jun;57(6):604–607. doi: 10.1038/bjc.1988.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Duggan D. B. Is adjuvant therapy justified for women with small breast cancers? J Clin Oncol. 1988 Sep;6(9):1520–1520. doi: 10.1200/JCO.1988.6.9.1520. [DOI] [PubMed] [Google Scholar]
  12. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–484. doi: 10.1056/NEJM198902233200802. [DOI] [PubMed] [Google Scholar]
  13. Fisher B., Redmond C., Dimitrov N. V., Bowman D., Legault-Poisson S., Wickerham D. L., Wolmark N., Fisher E. R., Margolese R., Sutherland C. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989 Feb 23;320(8):473–478. doi: 10.1056/NEJM198902233200801. [DOI] [PubMed] [Google Scholar]
  14. Fisher B., Redmond C., Fisher E. R., Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988 Jul;6(7):1076–1087. doi: 10.1200/JCO.1988.6.7.1076. [DOI] [PubMed] [Google Scholar]
  15. Friedman M. A., Dorr F. A., Perloff M. Adjuvant therapy for breast cancer patients with negative lymph nodes. NCI Monogr. 1986;(1):139–144. [PubMed] [Google Scholar]
  16. Henderson I. C. Adjuvant systemic therapy for early breast cancer. Curr Probl Cancer. 1987 May-Jun;11(3):125–207. [PubMed] [Google Scholar]
  17. Huseby R. A., Ownby H. E., Frederick J., Brooks S., Russo J., Brennan M. J. Node-negative breast cancer treated by modified radical mastectomy without adjuvant therapies: variables associated with disease recurrence and survivorship. J Clin Oncol. 1988 Jan;6(1):83–88. doi: 10.1200/JCO.1988.6.1.83. [DOI] [PubMed] [Google Scholar]
  18. Héry M., Gioanni J., Lalanne C. M., Namer M., Courdi A. The DNA labelling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res Treat. 1987;9(3):207–211. doi: 10.1007/BF01806381. [DOI] [PubMed] [Google Scholar]
  19. Kallioniemi O. P., Blanco G., Alavaikko M., Hietanen T., Mattila J., Lauslahti K., Koivula T. Tumour DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer. 1987 Nov;56(5):637–642. doi: 10.1038/bjc.1987.258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kardinal C. G., Donegan W. L. Second cancers after prolonged adjuvant thiotepa for operable carcinoma of the breast. Cancer. 1980 Apr 15;45(8):2042–2046. doi: 10.1002/1097-0142(19800415)45:8<2042::aid-cncr2820450809>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  21. Levine M. N., Gent M., Hirsh J., Arnold A., Goodyear M. D., Hryniuk W., De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988 Feb 18;318(7):404–407. doi: 10.1056/NEJM198802183180703. [DOI] [PubMed] [Google Scholar]
  22. Ludwig Breast Cancer Study Group Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med. 1988 Sep 15;319(11):677–683. doi: 10.1056/NEJM198809153191104. [DOI] [PubMed] [Google Scholar]
  23. Macias A., Azavedo E., Hägerström T., Klintenberg C., Pérez R., Skoog L. Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res. 1987 May-Jun;7(3 Pt B):459–464. [PubMed] [Google Scholar]
  24. McGuire W. L. Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol. 1988 Jul;6(7):1071–1072. doi: 10.1200/JCO.1988.6.7.1071. [DOI] [PubMed] [Google Scholar]
  25. Meyer J. S. Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma. NCI Monogr. 1986;(1):25–28. [PubMed] [Google Scholar]
  26. Moon T. E., Jones S. E., Bonadonna G., Valagussa P., Powles T., Buzdar A., Montague E. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol. 1987 Oct;10(5):396–403. doi: 10.1097/00000421-198710000-00006. [DOI] [PubMed] [Google Scholar]
  27. Moot S. K., Peters G. N., Cheek J. H. Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma. Cancer. 1987 Aug 1;60(3):382–385. doi: 10.1002/1097-0142(19870801)60:3<382::aid-cncr2820600316>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  28. Nealon T. F., Jr, Nkongho A., Grossi C. E., Ward R., Nealon C., Gillooley J. F. Treatment of early cancer of the breast (T1N0M0 and T2N0M0) on the basis of histologic characteristics. Surgery. 1981 Mar;89(3):279–289. [PubMed] [Google Scholar]
  29. Pritchard K. I. Systemic adjuvant therapy for node-negative breast cancer: proven or premature? Ann Intern Med. 1989 Jul 1;111(1):1–4. doi: 10.7326/0003-4819-111-1-1. [DOI] [PubMed] [Google Scholar]
  30. Pugesgaard T., Von Eyben F. E. Bilateral optic neuritis evolved during tamoxifen treatment. Cancer. 1986 Jul 15;58(2):383–386. doi: 10.1002/1097-0142(19860715)58:2<383::aid-cncr2820580232>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  31. Ribeiro G., Swindell R. The Christie hospital adjuvant tamoxifen trial--status at 10 years. Br J Cancer. 1988 Jun;57(6):601–603. doi: 10.1038/bjc.1988.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Russo J., Frederick J., Ownby H. E., Fine G., Hussain M., Krickstein H. I., Robbins T. O., Rosenberg B. Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol. 1987 Aug;88(2):123–131. doi: 10.1093/ajcp/88.2.123. [DOI] [PubMed] [Google Scholar]
  33. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  34. Sears H. F., Janus C., Levy W., Hopson R., Creech R., Grotzinger P. Breast cancer without axillary metastases. Are there high-risk biologic subpopulations? Cancer. 1982 Nov 1;50(9):1820–1827. doi: 10.1002/1097-0142(19821101)50:9<1820::aid-cncr2820500928>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  35. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]
  36. Thorpe S. M., Rose C., Rasmussen B. B., Mouridsen H. T., Bayer T., Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 1987 Nov 15;47(22):6126–6133. [PubMed] [Google Scholar]
  37. Valagussa P., Bonadonna G., Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978 Mar;41(3):1170–1178. doi: 10.1002/1097-0142(197803)41:3<1170::aid-cncr2820410355>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  38. Wittes R. E. Of clinical alerts and peer review. J Natl Cancer Inst. 1988 Sep 7;80(13):984–985. doi: 10.1093/jnci/80.13.984. [DOI] [PubMed] [Google Scholar]
  39. van de Velde C. J., Gallager H. S., Giacco G. G. Prognosis in node-negative breast cancer. Breast Cancer Res Treat. 1986;8(3):189–196. doi: 10.1007/BF01807331. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES